Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HRH2 | P25021 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | FABP6 | P51161 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | LSS | P48449 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313865 | 0.91 | HRH1 (0.52) | ALDH1A1MAPTLMNAHPGDTSHR | |
| SCHEMBL314412 | 0.89 | HRH2 (0.55) | HRH2HRH1DRD2DRD4DRD3 | |
| SCHEMBL314343 | 0.88 | MC4R (0.60) | ALDH1A1LMNATSHRHTTKMT2A | |
| SCHEMBL314250 | 0.86 | HTR1A (0.54) | ALDH1A1MAPTLMNAHPGDTSHR | |
| SCHEMBL11093397 | 0.84 | DRD2 (0.70) | PLA2G7MGLLABHD6ALDH1A1MAPT | |
| SCHEMBL23142617 | 0.80 | CACNA1G (0.51) | PLA2G7MGLLABHD6ALDH1A1KMT2A | |
| SCHEMBL2056138 | 0.78 | LMNA (0.69) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL14438075 | 0.77 | ALDH1A1 (0.60) | PLA2G7MGLLABHD6ALDH1A1MAPT | |
| SCHEMBL27839623 | 0.77 | MAPT (0.49) | ALDH1A1MAPTLMNAHPGDTSHR | |
| SCHEMBL5536182 | 0.76 | VEGFA (0.68) | PLA2G7MGLLABHD6MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | claimed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | claimed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | PLA2G7 261/4885MGLL 104/4885ABHD6 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.